Cardio And Metabolic Deals, Launches Falter – Will Innovation Help?
Despite the high unmet medical need in the cardiovascular and metabolic indications, companies are increasingly reluctant to make deals in the sector. But unique therapeutic approaches to diseases could bring new life.
You may also be interested in...
Lilly lowers expectations for Cymbalta; Celgene’s Abraxane continues with strong sales; Bristol touts the potential of Eliquis and Bydureon, despite slow sales; Ornskov discusses One Shire plan; BioMarin readies fifth compound for the clinic, and more.
Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.